# Bafna Pharmaceuticals (NSE: BAFNAPH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/BAFNAPH · Pivot · prices to 21 Oct 2026

Bafna Pharmaceuticals (NSE: BAFNAPH) closed at ₹475.00 on 21 Oct 2026. With a market capitalisation of ₹1,113 Cr, it ranks 1420th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 100.3× trailing earnings, against a return on equity of 0.0% in FY20. Over the past year the share price has risen 195.5%. Its 52-week range is ₹94.77 (16 Mar 2026) to ₹479.95 (21 Oct 2026); the last close is 1.0% below the high. Promoters held 75.00% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹475.00 |
| Market cap | ₹1,113 Cr |
| P/E (trailing) | 100.3 |
| ROE | 0.0% (FY20) |
| ROCE | −3.3% (FY20) |
| Debt to equity | -0.71 |
| 52-week high | ₹479.95 (21 Oct 2026) |
| 52-week low | ₹94.77 (16 Mar 2026) |
| 1-year return | +195.5% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY20 | ₹42 Cr | −₹24 Cr |
| FY19 | ₹43 Cr | −₹18 Cr |
| FY18 | ₹47 Cr | −₹17 Cr |
| FY17 | ₹65 Cr | −₹19 Cr |
| FY16 | ₹85 Cr | −₹15 Cr |
| FY15 | ₹98 Cr | ₹6 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 75.00%
- Foreign institutions: 9.34%
- Non-institutions: 15.66%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [GPT Healthcare](https://app.pivotnow.in/stock/GPTHEALTH) | ₹139.50 | ₹1,145 Cr | 27.1 | — |
| [Bajaj Healthcare](https://app.pivotnow.in/stock/BAJAJHCARE) | ₹339.90 | ₹1,144 Cr | 50.4 | — |
| [Lincoln Pharmaceuticals](https://app.pivotnow.in/stock/LINCOLN) | ₹533.40 | ₹1,068 Cr | 12.2 | — |
| [Sigachi Industries](https://app.pivotnow.in/stock/SIGACHI) | ₹26.70 | ₹1,020 Cr | — | — |
| [Laxmi Dental](https://app.pivotnow.in/stock/LAXMIDENTL) | ₹182.10 | ₹1,001 Cr | 34.6 | — |
| [Themis Medicare](https://app.pivotnow.in/stock/THEMISMED) | ₹100.30 | ₹924 Cr | — | — |

## Questions and answers

### What is the share price of Bafna Pharmaceuticals today?

Bafna Pharmaceuticals (NSE: BAFNAPH) last closed at ₹475.00 on 21 Oct 2026. Its 52-week high is ₹479.95 and its 52-week low is ₹94.77.

### What is the market cap of Bafna Pharmaceuticals?

Bafna Pharmaceuticals' market capitalisation is ₹1,113 Cr (₹1,113 Cr) at the 19 Oct 2026 close, ranking 1420th among the NSE companies Pivot tracks.

### What is the P/E ratio of Bafna Pharmaceuticals?

Bafna Pharmaceuticals trades at a trailing P/E of 100.3. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 34.6.

### What is the ROE and ROCE of Bafna Pharmaceuticals?

Return on equity was 0.0% in FY20 and return on capital employed was −3.3% in FY20 (consolidated figures).

### Is Bafna Pharmaceuticals a debt-free company?

Bafna Pharmaceuticals is close to debt-free: its debt-to-equity ratio was -0.71 in FY20.

### How has Bafna Pharmaceuticals stock performed over the last year?

Bafna Pharmaceuticals' share price has risen 195.5% over the past year, +105.5% over three months and +51.3% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Bafna Pharmaceuticals?

As of 30 Jun 2026: promoters 75.00%, foreign institutions 9.34%, non-institutions 15.66%.

### Who are Bafna Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to Bafna Pharmaceuticals by market cap are GPT Healthcare, Bajaj Healthcare, Lincoln Pharmaceuticals, Sigachi Industries, Laxmi Dental and Themis Medicare.

### Is Bafna Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Bafna Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BAFNAPH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.